C-MER Eye Care Holdings Limited (HK:3309)
:3309
Top Page
C-MER Eye Care Holdings Limited
(3309)
Select Model
Select Model
Rating:47Neutral
Price Target:
HK$1.50
â–¼(-11.76% Downside)
Action:ReiteratedDate:10/18/25
C-MER Eye Care Holdings Limited's overall stock score is primarily impacted by its financial challenges, including declining profitability and cash flow issues. Technical analysis also indicates bearish momentum, and valuation metrics reflect negative earnings, contributing to a lower score. The company's strong equity position is a positive aspect, but immediate improvements in profitability and cash flow are necessary for a better outlook.
Positive Factors
Conservative balance sheet and low leverage
A high equity ratio and low debt-to-equity provide a durable solvency buffer, lowering financial risk and interest burden. This balance-sheet strength gives the company flexibility to fund operations, invest in clinics or technology, and withstand demand shocks without relying heavily on external financing.
Negative Factors
Severe cash flow generation weakness
Zero operating and free cash flow undermines the company's ability to fund capital expenditure, service working capital needs, and sustain investments without external capital. This liquidity weakness is a material structural risk that constrains strategic options and increases reliance on financing until cash generation recovers.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet and low leverage
A high equity ratio and low debt-to-equity provide a durable solvency buffer, lowering financial risk and interest burden. This balance-sheet strength gives the company flexibility to fund operations, invest in clinics or technology, and withstand demand shocks without relying heavily on external financing.
Read all positive factors
C-MER Eye Care Holdings Limited (3309) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$1.61B
Dividend Yield1.2%
Average Volume (3M)495.46K
Price to Earnings (P/E)20.7
Beta (1Y)1.08
Revenue Growth2.05%
EPS Growth-285.88%
CountryHK
Employees2,041
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)0.04
Shares Outstanding1,232,342,900
10 Day Avg. Volume419,185
30 Day Avg. Volume495,465
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)1.41
Price to Sales (P/S)1.30
P/FCF Ratio19.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
C-MER Eye Care Holdings Limited Business Overview & Revenue Model
Company Description
C-MER Eye Care Holdings Ltd. engages in the provision of treatments and therapy services for ophthalmic diseases. It operates through the Provision of Ophthalmic Services and the Sale of Vision Aid Products segments. The company was founded by Shu...
How the Company Makes Money
C-MER Eye Care Holdings Limited generates revenue primarily through its clinical services, which encompass fees charged for surgical procedures, consultations, and diagnostic tests. The company has established several revenue streams, including pa...
C-MER Eye Care Holdings Limited Financial Statement Overview
Summary
Income Statement
55
Neutral
Balance Sheet
65
Positive
Cash Flow
40
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.93B | 1.91B | 1.92B | 1.73B | 1.11B | 699.54M |
| Gross Profit | 601.68M | 527.62M | 618.96M | 365.34M | 309.44M | 163.65M |
| EBITDA | 200.03M | 209.18M | 363.38M | 194.31M | 177.80M | 111.39M |
| Net Income | -115.98M | -135.16M | 62.00M | -21.88M | 21.86M | -6.25M |
Balance Sheet | ||||||
| Total Assets | 2.76B | 2.72B | 2.75B | 2.90B | 1.96B | 1.63B |
| Cash, Cash Equivalents and Short-Term Investments | 435.71M | 467.25M | 557.42M | 698.51M | 442.36M | 553.93M |
| Total Debt | 423.12M | 437.79M | 362.99M | 452.49M | 471.69M | 244.97M |
| Total Liabilities | 823.32M | 830.24M | 755.35M | 903.45M | 618.63M | 331.98M |
| Stockholders Equity | 1.78B | 1.75B | 1.85B | 1.87B | 1.33B | 1.29B |
Cash Flow | ||||||
| Free Cash Flow | 143.66M | 124.50M | 245.30M | 100.63M | 19.18M | -233.39M |
| Operating Cash Flow | 262.62M | 283.12M | 361.15M | 191.86M | 148.41M | 104.03M |
| Investing Cash Flow | -172.88M | -174.72M | -245.37M | -210.65M | -392.72M | -157.94M |
| Financing Cash Flow | -198.66M | -194.92M | -242.88M | 293.68M | 85.12M | 322.37M |
C-MER Eye Care Holdings Limited Technical Analysis
Negative
1.70
Price Trends
1.44
Negative
1.57
Negative
1.72
Negative
Market Momentum
-0.05
Negative
41.34
Neutral
65.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:3309, the sentiment is Negative. The current price of 1.7 is above the 20-day moving average (MA) of 1.34, above the 50-day MA of 1.44, and below the 200-day MA of 1.72, indicating a bearish trend. The MACD of -0.05 indicates Negative momentum. The RSI at 41.34 is Neutral, neither overbought nor oversold. The STOCH value of 65.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:3309.
C-MER Eye Care Holdings Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | HK$863.39M | 5.69 | 6.49% | 1.99% | -1.61% | -27.39% | |
68 Neutral | HK$1.94B | 4.06 | 7.38% | 9.29% | -3.19% | -20.30% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | HK$1.61B | 20.66 | 5.64% | 1.20% | 2.05% | -285.88% |
* Healthcare Sector Average
HK:3309
C-MER Eye Care Holdings Limited
1.31
-0.09
-6.43%
HK:1846
EuroEyes International Eye Clinic Limited
2.70
-0.19
-6.57%
HK:2219
Chaoju Eye Care Holdings Ltd.
2.75
0.37
15.55%
C-MER Eye Care Holdings Limited Corporate Events
C-MER Eye Care Disposes Stake in Apollo to Refocus Strategy
Dec 17, 2025
C-MER Eye Care Holdings Limited has signed an agreement with HKO to transfer its 55% equity interest in Apollo back to HKO. The transaction involves the cancellation of a bond previously issued as part of Apollo’s acquisition. With this disp...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.